Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (18)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Parrish, N. M.
Right arrow Articles by Dick, J. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Parrish, N. M.
Right arrow Articles by Dick, J. D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (1999) 43, 219-226
© 1999 The British Society for Antimicrobial Chemotherapy

Antimycobacterial activity of cerulenin and its effects on lipid biosynthesis

Nikki M. Parrishb, Francis P. Kuhajdaa, Henry S. Heinea, William R. Bishaib,c and James D. Dicka,b,*

a Department of Pathology, School of Medicine, Johns Hopkins University, Baltimore, MD b Department of Molecular Microbiology and Immunology, School of Public Health, Johns Hopkins University, Baltimore, MD, USA c Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, MD

Cerulenin is a potent inhibitor of fatty acid synthase (FAS) in a variety of prokaryotic and eukaryotic cells. Using a standardized mycobacterial susceptibility test, we have observed that cerulenin inhibits the growth of several species of mycobacteria, including tuberculous species such as Mycobacterium tuberculosis (H37Rv and clinical isolates) andMycobacterium bovis BCG (hereafter called BCG), as well as several non-tuberculous species: Mycobacterium smegmatis, the Mycobacterium avium-intracellulare complex (MAC), Mycobacterium kansasii and others. All species and strains tested, including multi-drug resistant isolates of M. tuberculosis, were susceptible to cerulenin with MICs ranging from 1.5 to 12.5 mg/L. Two-dimensional thin-layer chromatography revealed different inhibition patterns of lipid synthesis between tuberculous and non-tuberculous mycobacteria. Cerulenin treatment resulted in a relative increase in phospholipids and mycolic acids in MAC and M. smegmatis, whereas in cerulenin-treated BCG, phospholipids and mycolic acids diminished relative to controls. In addition, long-chain extractable lipids (intermediate in polarity), triglycerides and glycopeptidolipids decreased with cerulenin treatment in all three species of mycobacteria tested. Qualitative changes in several of these lipid classes indicate inhibition in the synthesis of intermediate and long-chain fatty acids. Our results suggest that cerulenin's primary effect may be inhibition of intermediate and long-chain lipid synthesis, with little effect on the synthesis of other lipid classes. In addition, the BCG-specific reduction in phospholipids and mycolic acids suggests the presence of a unique cerulenin-sensitive FAS system in tuberculous mycobacteria. Since pathogenic mycobacteria produce novel long-chain fatty acids, inhibition of fatty acid synthesis offers a potential target for the development of antimycobacterial drugs.

* Corresponding author. Johns Hopkins Medical Institutions, Department of Pathology/Division of Medical Microbiology, 600 N. Wolfe Street, Baltimore, MD 21287, USA. Tel:+1410-955-5077; Fax: 1 +410-614-8087; E-mail: jdick{at}pathlan.path.jhu.edu


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Evid Based Complement Alternat MedHome page
C. T. Higuchi, M. Sannomiya, F. R. Pavan, S. R. A. Leite, D. N. Sato, S. G. Franzblau, L. V. S. Sacramento, W. Vilegas, and C. Q. F. Leite
Byrsonima fagifolia Niedenzu Apolar Compounds with Antitubercular Activity
Evid. Based Complement. Altern. Med., December 17, 2008; (2008) nen077v1.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
N. M. Parrish, C. G. Ko, M. A. Hughes, C. A. Townsend, and J. D. Dick
Effect of n-octanesulphonylacetamide (OSA) on ATP and protein expression in Mycobacterium bovis BCG
J. Antimicrob. Chemother., October 1, 2004; 54(4): 722 - 729.
[Abstract] [Full Text] [PDF]

Home page
 J. Bacteriol.Home page
O. Zimhony, C. Vilcheze, and W. R. Jacobs Jr.
Characterization of Mycobacterium smegmatis Expressing the Mycobacterium tuberculosis Fatty Acid Synthase I (fas1) Gene
J. Bacteriol., July 1, 2004; 186(13): 4051 - 4055.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
L. Kremer, L. G. Dover, H. R. Morbidoni, C. Vilcheze, W. N. Maughan, A. Baulard, S.-C. Tu, N. Honore, V. Deretic, J. C. Sacchettini, et al.
Inhibition of InhA Activity, but Not KasA Activity, Induces Formation of a KasA-containing Complex in Mycobacteria
J. Biol. Chem., May 30, 2003; 278(23): 20547 - 20554.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
N. M. Parrish, T. Houston, P. B. Jones, C. Townsend, and J. D. Dick
In Vitro Activity of a Novel Antimycobacterial Compound, N-Octanesulfonylacetamide, and Its Effects on Lipid and Mycolic Acid Synthesis
Antimicrob. Agents Chemother., April 1, 2001; 45(4): 1143 - 1150.
[Abstract] [Full Text]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.